Interact with experts and peers.

Recent Posts

10 of 71 Shown
  • Will Healthcare Reform Challenge Our Ability to Prescribe Single-Tablet Regimens?

    William G. Powderly MD - 5/18/2015
    I recently encountered an unexpected challenge in my clinic after prescribing a single-tablet regimen for a newly diagnosed HIV-infected patient.
  • My Take on the Latest DHHS Guidelines: The Increasing Role for Integrase Inhibitors in First-line Therapy

    Daniel R. Kuritzkes MD - 5/15/2015
    With the latest update to the DHHS guidelines for ART, chances are you will be starting most patients on an integrase inhibitor–based regimen.
  • Analyzing NA-ACCORD: Should You Avoid Abacavir In Patients With Cardiovascular Risk?

    Josep M. Llibre MD - 5/15/2015 1 comment / Last Comment: 5/19/2015
    The recent NA-ACCORD data presented at CROI 2015 has reignited discussion on the potential association between abacavir exposure and MI. But there are several limitations of this analysis to consider before altering your practice.
  • Using Archived HIV-1 DNA Resistance Testing When Considering Switching: What Are the Limitations?

    Charles B. Hicks MD - 5/1/2015 1 comment / Last Comment: 5/19/2015
    As the enthusiasm for switching virologically suppressive ART regimens to simpler treatment options grows, one major concern is ensuring that the simpler regimen can maintain virologic suppression when unrecognized HIV drug resistance may be present in archived viruses.
  • Considerations on the Use of Fixed-Dosed Combination Therapy in a Patient With Multiple Comorbidities

    Eric S. Daar MD - 4/21/2015 1 comment / Last Comment: 5/19/2015
    In this case-based example, I describe the available options for single-tablet ART regimens in a patient with CVD risk factors and renal disease, including how recent data influence the management strategy.
  • How I Decided Whether to Stop a Potentially Inactive NRTI in a Patient Receiving a Suppressive Regimen

    Renslow Sherer MD - 4/17/2015 1 comment / Last Comment: 4/24/2015
    How does the risk of ongoing NRTI-related toxicity in a patient weigh up against the limited antiviral contribution to a suppressive regimen? The data that informed my decision.
  • Lessons Learned in the Clinic: Why a Complete Treatment History Is Essential Information for Treatment Simplification

    Joseph J. Eron, Jr. MD - 4/7/2015 3 comments / Last Comment: 5/18/2015
    A recent seemingly straightforward case of treatment simplification took an interesting turn about 10 months after switching therapy.
  • The Availability of Coformulated Cobicistat-Boosted Protease Inhibitors and the Impact on My Practice

    David A. Wohl MD - 3/18/2015 3 comments / Last Comment: 4/24/2015
    In both treatment-naive and virologically suppressed patients, the availability of fixed-dose cobicistat-boosted PIs makes me take another look at my management approach.
  • Single Pill vs Multicomponent Regimens: What Is the Impact on Patients?

    Charles B. Hicks MD - 2/24/2015 6 comments / Last Comment: 5/6/2015
    In 2015, most HIV-infected persons initiating first-line ART are prescribed a once-daily single-tablet regimen. I describe a recent complex case that made treatment selection challenging.
  • Will the Resistance Record With Newer Therapies Hold Up in Clinical Practice? Here’s My Take

    Mark A. Wainberg PhD - 2/23/2015 2 comments / Last Comment: 4/2/2015
    How I approach first-line therapy in my practice in light of clinical trial data demonstrating a high barrier to dolutegravir resistance.
10 of 71 Shown
Show 10 More